JP2025500412A5 - - Google Patents
Info
- Publication number
- JP2025500412A5 JP2025500412A5 JP2024537896A JP2024537896A JP2025500412A5 JP 2025500412 A5 JP2025500412 A5 JP 2025500412A5 JP 2024537896 A JP2024537896 A JP 2024537896A JP 2024537896 A JP2024537896 A JP 2024537896A JP 2025500412 A5 JP2025500412 A5 JP 2025500412A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- qol
- patient
- questionnaire
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163293070P | 2021-12-22 | 2021-12-22 | |
| US63/293,070 | 2021-12-22 | ||
| US202263305550P | 2022-02-01 | 2022-02-01 | |
| US63/305,550 | 2022-02-01 | ||
| US202263335535P | 2022-04-27 | 2022-04-27 | |
| US63/335,535 | 2022-04-27 | ||
| US202263359717P | 2022-07-08 | 2022-07-08 | |
| US63/359,717 | 2022-07-08 | ||
| US202263382223P | 2022-11-03 | 2022-11-03 | |
| US63/382,223 | 2022-11-03 | ||
| US202263386489P | 2022-12-07 | 2022-12-07 | |
| US63/386,489 | 2022-12-07 | ||
| PCT/US2022/082213 WO2023122713A1 (en) | 2021-12-22 | 2022-12-22 | Fitusiran for use in improving patient-reported outcome in hemophilia patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025500412A JP2025500412A (ja) | 2025-01-09 |
| JP2025500412A5 true JP2025500412A5 (https=) | 2026-01-05 |
Family
ID=85227438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024537896A Pending JP2025500412A (ja) | 2021-12-22 | 2022-12-22 | 血友病患者において患者報告アウトカムを改善するのに使用するためのフィツシラン |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250064842A1 (https=) |
| EP (1) | EP4452280A1 (https=) |
| JP (1) | JP2025500412A (https=) |
| KR (1) | KR20240138572A (https=) |
| AU (1) | AU2022419588A1 (https=) |
| CA (1) | CA3243297A1 (https=) |
| IL (1) | IL313677A (https=) |
| MX (1) | MX2024007894A (https=) |
| TW (1) | TW202342065A (https=) |
| WO (1) | WO2023122713A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025171279A1 (en) * | 2024-02-09 | 2025-08-14 | Genzyme Corporation | Treatment of hemophilia with fitusiran |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| KR20180095843A (ko) | 2015-12-07 | 2018-08-28 | 젠자임 코포레이션 | Serpinc1-연관 장애의 치료를 위한 방법 및 조성물 |
| TW202434265A (zh) | 2017-07-10 | 2024-09-01 | 美商健贊公司 | 於患有血友病之個體中治療出血事件之方法及組成物 |
| WO2022120291A1 (en) * | 2020-12-06 | 2022-06-09 | Genzyme Corporation | Treatment of hemophilia with fitusiran |
-
2022
- 2022-12-21 TW TW111149131A patent/TW202342065A/zh unknown
- 2022-12-22 KR KR1020247024462A patent/KR20240138572A/ko active Pending
- 2022-12-22 EP EP22857063.6A patent/EP4452280A1/en active Pending
- 2022-12-22 AU AU2022419588A patent/AU2022419588A1/en active Pending
- 2022-12-22 MX MX2024007894A patent/MX2024007894A/es unknown
- 2022-12-22 CA CA3243297A patent/CA3243297A1/en active Pending
- 2022-12-22 US US18/723,352 patent/US20250064842A1/en active Pending
- 2022-12-22 WO PCT/US2022/082213 patent/WO2023122713A1/en not_active Ceased
- 2022-12-22 JP JP2024537896A patent/JP2025500412A/ja active Pending
- 2022-12-22 IL IL313677A patent/IL313677A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023531679A5 (https=) | ||
| Janson et al. | Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours | |
| ES2555279T3 (es) | Neuroprotección en enfermedades desmielinizantes | |
| JP2022123073A (ja) | Ｅｆｐの治療または低減方法 | |
| CA2542726A1 (en) | Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes | |
| CN1094642A (zh) | 治疗组合物 | |
| EP2515926A1 (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
| Shayan et al. | Use of propranolol in treating hemangiomas | |
| TW202417035A (zh) | 提派肽(tirzepatide)組合物及用途 | |
| JP2025500412A5 (https=) | ||
| JP2023544249A5 (https=) | ||
| JP2023541170A5 (https=) | ||
| RU2024120372A (ru) | Фитусиран для применения в улучшении сообщаемого пациентом исхода у пациентов с гемофилией | |
| WO2023028554A1 (en) | Glp-1r agonists for use in a treatment of neurological impairment associated with viral infection | |
| ES2929379T3 (es) | Métodos para el tratamiento de infecciones por coronavirus | |
| Neal | The treatment of acute infections of the central nervous system with sulfanilamide | |
| Kasgari et al. | Combination therapy with remdisivir and tocilizumab for covid-19: Lessons for futures studies | |
| KR20000010880A (ko) | 종양에 대한 숙주 방어 기작의 자극 | |
| RU2389499C1 (ru) | Способ лечения больных с гипербилирубинемией | |
| RU2147841C1 (ru) | Способ лечения папилломатоза гортани | |
| Sands et al. | A31 MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY-TO-SEVERELY ACTIVE UC: IMPROVEMENT IN IBDQ SCORES IN PARTICIPANTS OF LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIALS | |
| RU2416413C1 (ru) | Средство для лечения кровопотери ("спаскровь") | |
| Han | Safety of Topical Calcineurin Inhibitors for Hailey-Hailey Disease | |
| RU2005489C1 (ru) | Способ лечения острого сепсиса | |
| RU2240824C1 (ru) | Способ лечения острого вирусного гепатита в |